Prescribing in Chronic Renal Disease. Who has chronic renal disease (CKD)? CKD stages 1-V How common is it? Creatinine v GFR Basic Principles Scenarios.

Slides:



Advertisements
Similar presentations
1. 2 ACEI inhibit angiotensin converting enzyme in the body. ACEI inhibit angiotensin converting enzyme in the body. Enzyme maintains balance between:
Advertisements

LECTURE FILES f:\callab\lectures\dhollo.. PHARMACOLOGY route of elimination –kidney –liver –both.
Chronic kidney disease
Chronic kidney disease
CKD ML/LH What are people hoping to cover from the session today?
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Renal Board Review Brenda Shinar, MD. Question 1. Answer: A: Combinaton drug therapy.
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Drug therapy in renal failure Kari Laine, MD, PhD University of Turku & medbase Ltd.
Management of children with CKD in a DGH M Shenoy Consultant Paediatric Nephrologist RMCH Nephrology for the General Paediatrician Meeting Manchester.
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Measurement and preservation of residual renal function (RRF) in haemodialysis patients Elizabeth Lindley and David Keane Leeds Teaching Hospitals NHS.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
EXCRETORY SYSTEM EXCRETORY SYSTEM Karen Lancour Patty Palmietto National Bio Rules National Event Committee Chairman Supervisor – A&P.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Cardiovascular Hot topics Dr Saqib Mahmud, MRCP(UK)
RENAL BLOOD TESTS WHAT DO THEY MEAN, WHERE TO GO FOR WHAT TO DO.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
 Cure Pathologic Fear of Hypertension  Create Rational Approach to Drug Choice  Complement Rational Choice with Pearls  Consolidate new information.
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Loop diuretics VS venous ultrafiltration in cardio-renal syndrome Radek Debiec SHO Renal Medicine LGH Sept 2013.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
RENAL DISEASE IN DIABETES
CHRONIC RENAL FAILURE JAKUB ZÁVADA KLINIKA NEFROLOGIE 1.LF UK.
HYPERTENSION NMP. How Common? 25% UK adults 25% UK adults > 50% adults over 60 > 50% adults over 60.
Ambulatory Care Pharmacy
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Selection of Antihypertensive Drug. BP ClassificationSystolic BP, mm Hg Diastolic BP, mm Hg Normal
 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
Excretion of Drugs By the end of this lecture, students should be able to Identify main and minor routes of Excretion including renal elimination and biliary.
CKD update Dr Saqib Mahmud MRCP(UK),MRCGP. Chronic kidney disease Defined by a reduced eGFR, proteinuria, haematuria and/ or structural abnormalities.
Section 5: Configuration of healthcare to manage CKD.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Pharmacology Department
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Bicarbonate-Based Solutions in the Management of Acute Kidney Injury Vania Cecilia Prudencio-Ribera, MD 1 ; Universidad Mayor de San Simón, School of Medicine,
Safety update Anthony Ormerod. Why is safety important? Clinical trial / European directive MHRA / governance Severe disease Patients have large burden.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Diuresis By Dr. Ola Mawlana.
Sodium Reabsorption, Diuretics, and Diet Vivek Bhalla, MD Division of Nephrology Stanford University School of Medicine September 14th, 2015.
Chronic Kidney Disease: Treatment. Slowing the Progression of CKD Protein Restriction – KDOQI guidelines g/kg per day – Sufficient energy.
Dr. Aya M. Serry Renal Failure Renal failure is defined as a significant loss of renal function in both kidneys to the point where less than 10.
Case I A 47 old male presents to your office for a yearly checkup. He smokes 40 cigarette/day, and examination detect wheezy chest and bronchospasm. His.
Sodium Reabsorption, Diuretics, and Diet Vivek Bhalla, MD Division of Nephrology Stanford University School of Medicine September 14th, 2015.
Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.
Application of the “Steady-state” Principle Vivek Bhalla, MD Division of Nephrology Stanford University School of Medicine September 1st 2015.
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.
Internal Medicine Workshop Series Laos September /October 2009.
Heart Failure  Dfinition:  Clinical features  Underlying causes of HF include Arteriosclerotic heart disease, MI, hypertensive heart disease, valvular.
Medicines and CKD Nikki Lawton Medicines Optimisation Pharmacist NMCCG.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Clinical Management of primary hypertension
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Diuretics Thiazides are the preferred type of diuretic for treating hypertension, and all are equally effective in lowering blood pressure. In patients.
Based on work of the PPRNet
Presented By Dr / Said Said Elshama
HTN Cases Pharmacotherapy - 1.
Medication and Acute Kidney Injury
Kidney and Drugs.
Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,
Nat. Rev. Cardiol. doi: /nrcardio
Meeting the challenges of the new K/DOQI guidelines
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Internal Medicine Workshop Series Laos September /October 2009
Presentation transcript:

Prescribing in Chronic Renal Disease

Who has chronic renal disease (CKD)? CKD stages 1-V How common is it? Creatinine v GFR Basic Principles Scenarios

Effect of ageing on renal function

Age bands eGFR (ml/min/1.73 m2) Mean Cov Declining eGFR

Age bands eGFR (ml/min/1.73 m2) Mean Cov Mean-1sd Declining eGFR ■

Age bands eGFR (ml/min/1.73 m2) Mean Cov Mean-1sd Mean-2sd Declining eGFR ■ ▲ ▲

Age bands eGFR (ml/min/1.73 m2) Mean Cov Mean-1sd Mean-2sd Declining eGFR ■ ▲ ▲ – – – – – – – – – – –

Chronic Kidney Disease KDOQI guidelines CKD Stage I CrCl > 90 with kidney disease Stage II CrCl Stage IIICrCl Stage IVCrCl Stage VCrCl <15

Chronic Kidney Disease CKD Stage No of patients in Coventry (I+II) (III) (IV) (V) 93,826 10, Total Total III to V 106,366 12,540 Raymond et al. 2004

Beware of plasma/serum creatinine interpretation Creatinine  mol/l GFR ml/min CKD III

Principles Loading dose Maintenance dose Dose interval Excretion / Secretion Therapeutic range Renal toxicity

Principles Loading dose Maintenance dose If start with a maintenance dose then will take some time to reach therapeutic concentration eg Amiodarone / Digoxin. If look up maintenance dose in BNF in renal failure and prescribe small dose then will take ages to reach target. How quick is a response required? Give normal loading dose and then a renal adjusted maintenance dose to ensure effective therapy.

Digoxin Loading 1000ugs over 24 hours Maintenance If anuric (on dialysis) need 62.5 ugs daily For every 30mls of GFR add another 62.5 ugs. If GFR >90 will need 250ugs daily.

Dose interval Vancomycin Loading dose 1000mgs first dose Maintenance1000mgs every 5-7 days for dialysis patient Monitor with levels

Excretion / secretion Trimethoprim / Nitrofurantoin These drugs work well because they are secreted into the renal tubules and achieves good therapeutic levels. Favoured options for UTI. Less useful for systemic infections. If GFR reduced excretion and tubular secretion is reduced and the drug is less effective. Less reliable as antibiotic for UTI in renal patients. Still used by many doctors as popular choice for UTI.

Therapeutic range May be narrow or wide - toxicity  Aminoglycosides  Antibiotics  Cardiac Drugs – Digoxin, Amiodarone  Analgesics – especially post op. Delayed action can lead to overdose. “No-one should be in pain”

Renal Toxicity ACEI / NSAID’s Action on the kidney can be directly deleterious Effects on glomerular filtration pressure Can predispose a kidney to hypoperfusion. More likely to cause a problem in context of chronic renal disease (reduced renal reserve). Common cause of admission to hospital Common cause of renal referral Common cause of death

Afferent Efferent Angiotensin II (vasoconstrictor) Prostacycline (vasodilator) Glomerular filtration pressure

Renal Toxicity ACEI / NSAID’s These are good drugs Widely prescribed Modern drugs are very powerful Many hospital admissions are down to drug adverse effects Role of trials Evidence based medicine - protocols Common sense Doctors v Robots

Scenario 75 yr old lady being treated for hypertension and mild heart failure. 1) Prescribed diuretics as first line. Diuretic used to reduce salt load. Potassium sparing. 2) Subsequently prescribed Spironolactone (25mgs) to improve outcome from heart failure. 3) ARB added to improve BP and reduce diuretic load

Age 75 Clinic BP:185/90 Drug therapy: Hydrochlorothiazide /Amiloride 50/5 mg, Spironolactone 25 mg o.d., Torasemide 2.5 mg o.d, Aspirin 75 mg o.d., Simvastatin 40 mg o.d., Conditions:High BP, type 2 diabetes, chronic renal failure This lady came to see me again today. Her creatinine has settled down at 147 with an eGFR of 30 and potassium is 4 mmol/L, despite the heavy use of loop diuretics and thiazide. I think it is time to break the vicious circle of the excessive use of diuretics in this lady and I have taken the liberty of advising to start Losartan at a dose of 50 mg or even 25 mg for a few weeks in order to reduce BP until she sees me again.

Comments BHS says ACEI is first line for hypertension especially in the <55 year age group. Diuretics are cheap and effective in mild hypertension and are often first line in the elderly Spironolactone has been shown to improve survival in heart failure. Lots of trial evidence for these individual drugs.

What happened next?

18/12/ : /12/ : /12/ : /12/ : /12/ : /12/ : /12/ : /11/ : /11/ : /09/ : /08/ : /07/ : ARB added Admitted – ill!

Trials and their application What type of patient was recruited. Do we stick to the indications highlighted by the trial. How many 80 and 90 year olds in trials?? Common sense Trials and protocols guide practise in the individual patient.

Cardiology and hyperkalaemia IHD Spironolactone ACEI’s NSAID’s Hyperkalaemia R I P

Scenario “Please see and advise on Mr X who has CKD and in whom we are having difficulty in controlling his potassium which is 6.5”. Mr X is a diabetic and is unwell with nausea. He has been on an insulin sliding scale according to Trust protocol for several days. How would you prescribe the sliding scale?

Scenario Patient with CKD IV admitted with fracture of neck of femur. On ACEI for hypertension. Surgery successful. Patient in pain and started on MST 10mgs bd and regular oramorph. Also given Ibuprofen for additional pain control. This is in keeping with analgesic protocol on the ward. Day 1 Pt awake and sat up. Catheter in situ. Day 2 Patient drowsy so physio postponed. Day 3 ????

Day 3 More drowsy and probable infection, ? Chest or urine. Cultures taken. Given Augmentin and Gentamicin (protocol?) How would you write up the gentamicin? Day 4 Unconscious. Urea 45, K 7.6 Call for help!! Day 6 RIP Any comments?